Skip to content

Depression: all studies

Page 165 of 1,034: studies 1,641 to 1,650 of 10,336, newest first. Back to the depression overview

Research

Medicalisation of Ayahuasca as a Depression Treatment

The Maastricht Journal of Liberal Arts September 19, 2023 Elena Gomel Cordeiro

This paper examines the possible consequences of medicalising the psychedelic Ayahuasca to be used as a treatment for depression. Through a science and technology studies (STS) understanding of the social construction of scientific facts, I consider how traditional indigenous uses of Ayahuasca are translated into Western medicine. Two special points of attention are: (1) the cultural...

DOI: 10.26481/mjla.2023.v14.912 (opens in new tab) Ayahuasca Indigenous Biomedicine Medicalization +7

The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression

Frontiers in Psychiatry September 19, 2023 Nicolas Garel, Jessica Drury, Julien Thibault Lévesque et al. 32 citations

Background Subanesthetic ketamine has accumulated meta-analytic evidence for rapid antidepressant effects in treatment-resistant depression (TRD), resulting in both excitement and debate. Many unanswered questions surround ketamine’s mechanisms of action and its integration into real-world psychiatric care, resulting in diverse utilizations that variously resemble electroconvulsive therapy,...

DOI: 10.3389/fpsyt.2023.1268832 (opens in new tab) Ketamine Biopsychosocial model Psychotherapist Clinical psychology

The not so little matter of how to dose ketamine in patients with depression

Acta Psychiatrica Scandinavica September 17, 2023 Chittaranjan Andrade 5 citations

It is almost axiomatic with most drugs and for most disorders in psychiatry that whatever elicits response and remission during the acute phase of illness will prevent relapse and recurrence of illness during the maintenance phase of treatment. Logically, this principle should apply to ketamine, as well, when the drug is used for patients with depression; thus, at the very least, the treatment,...

Propofol for treatment resistant depression: A randomized controlled trial

medRxiv September 15, 2023 Scott C. Tadler, Keith Jones, Carter Lybbert et al. 7 citations preprint

Background: Anesthetic agents including ketamine and nitrous oxide have shown antidepressant properties when appropriately dosed. Our recent open-label trial of propofol, an intravenous anesthetic known to elicit transient positive mood effects, suggested that it may also produce robust and durable antidepressant effects when administered at a high dose that elicits an electroencephalographic...

The psychedelic experience and treatment‐resistant depression

World Psychiatry September 15, 2023 Guy M. Goodwin

Interest in the use of serotonergic agonists such as psilocybin in treatment-resistant depression (TRD) has grown more quickly than the evidence on which to base a final opinion, as emphasized by McIntyre et al1 in their review. Psilocybin, once metabolized to psilocin, activates 5-HT2A receptors, enhancing GABA function in local circuits in the cortex and increasing connectivity between...

Using mindfulness-based stress reduction to relieve loneliness, anxiety, and depression in cancer patients: A systematic review and meta-analysis.

Medicine September 15, 2023 Junye Yu, Mingyue Han, Fengru Miao et al. 26 citations

Mindfulness-based stress reduction (MBSR) has been suggested as an effective mind-body approach for relieving stress in patients with chronic diseases. As of yet, there is no conclusive research on MBSR's role in reducing affective disorders among cancer patients. A systematic review and meta-analysis was conducted to determine whether MBSR has an impact on loneliness, anxiety, and depression...

Short-term cognitive effects of repeated-dose esketamine in adolescents with major depressive disorder and suicidal ideation: a randomized controlled trial

Child and Adolescent Psychiatry and Mental Health September 14, 2023 Xiaofeng Lan, Chengyu Wang, Fan Zhang et al. 22 citations

BACKGROUND: Ketamine and its enantiomer have rapid and robust effects on depressive symptom and suicidal ideation. Little is known about their cognitive effects in adolescents. We aimed to evaluate the short-term effect of esketamine on cognition in adolescents with major depressive disorder (MDD) and suicidal ideation. METHOD: In this randomized-controlled trial, 51 participants aged 13-18...

Impact of Mindfulness to Relieve Stress, Anxiety, and Depression among the University Students of Odisha

International Journal of Multidisciplinary Approach Research and Science September 11, 2023 Nilamani Maharana, Rupashree Goswami, Deepak Kumar Behera 3 citations

Background of the study: Stress, anxiety, and depression are rather common during higher education time and have a bad effect on academic performance. There is evidence that mindfulness practices can enhance the mental health and exist over how stress, anxiety, and depression are affected. In this study, the post-graduate students of Odisha were assessed to see how well mindfulness treated...

Classic Psychedelics for the Treatment of Depressive Disorders: An Update for Psychiatrists in Training

American Journal of Psychiatry Residents Journal September 8, 2023 Lawrence Canale, Dhvanit Raval, Preet Chatha et al.

Psychedelics as therapeutic agents have generated significant attention from clinicians and media sources in recent years. The authors provide an update to the psychiatric trainee on the evidence for psychedelics in the treatment of major depressive disorder and treatment-resistant depression. Many modern clinical trials of the classic, serotonergic psychedelics, such as psilocybin, ayahuasca,...